Dr Michele Denker, MD | |
Ft Belvoir Community Hospital, 9300 Dewitt Loop, Ft Belvoir, VA 22060-0000 | |
(919) 610-8906 | |
Not Available |
Full Name | Dr Michele Denker |
---|---|
Gender | Female |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | Ft Belvoir Community Hospital, Ft Belvoir, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497890925 | NPI | - | NPPES |
28348 | Other | NC | BCBS |
20-5514002 | Other | NC | TAX ID |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 39363 (North Carolina) | Secondary |
2084P0800X | Psychiatry & Neurology - Psychiatry | 0101263646 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Michele Denker, MD Ft Belvoir Community Hospital, 9300 Dewitt Loop, Ft Belvoir, VA 22060-0000 Ph: (919) 610-8906 | Dr Michele Denker, MD Ft Belvoir Community Hospital, 9300 Dewitt Loop, Ft Belvoir, VA 22060-0000 Ph: (919) 610-8906 |
News Archive
TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, today announced the formation of a wholly owned subsidiary: TSO3 Corporation, structured under the laws of the State of Delaware, and located in the State of South Carolina, USA.
Borderline Personality Disorder, or BPD, is the most common personality disorder in Australia, affecting up to 5% of the population at some stage, and Flinders University researchers warn more needs to be done to meet this high consumer needs.
Exposure to the endocrine disrupting chemicals bisphenol A, triclosan and phthalates is ubiquitous in the United States, raising concerns that they may affect health. With a new four-year, $1.5 million grant from the National Institutes of Health, Brown University epidemiologist Joseph Braun will try to close a gap in research: the effect of these exposures on the brain and thyroid during pregnancy and childhood.
Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.
› Verified 5 days ago
Jocelyn Kilgore, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 5980 9th St Bldg 1259, Ft Belvoir, VA 22060 Phone: 571-231-1210 | |
Jim R. Monestime, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 9300 Dewitt Loop, Ft Belvoir, VA 22060 Phone: 571-231-2408 | |
Dr. Robyn Treadwell, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 9300 Dewitt Loop, Ft Belvoir, VA 22060 Phone: 571-231-7233 |